Salesforce is up after-hours, a tweet explains the reason. 
https://x.com/StockMKTNewz/status/1978583433027657813
1 Like
Too bad for those who joined in at the $10 mark to follow the forum gurus. But no worries, new non-investment recommendations will come before dark, once they are first dug out from Reddit’s pump&dump thread and deployed to the buy/sell thread with flimsy reasoning. This 72-hour cycle, ‘chips on black or red’ type of betting has nothing to do with investing, but it seems surprisingly effective, as long as one remembers to jump off the ride before the final stop.
57 Likes
No leverage, no gain 
From crypto ETFs, everything except Bitcoin would have already gone to zero in the latest crash
What caused these to drop, by the way?
6 Likes
I understand that lost profits are frustrating when one has failed to capitalize on the momentum, but blaming others in this individual game is foolish.
If we look at how much hydrogen and AI stocks have brought positive returns to portfolios during the past 6 months, then surely there are quite a few happy shareholders here who followed “forum gurus.”
Should the guru also announce upcoming sales in advance so that no one gets upset?
23 Likes
If that forum guru referred to @Tokarczuk, then he/she has very accurately reported purchases, sales, and even their targets in these.
Surely it’s every follower’s own responsibility to set up stop-losses for their purchases or consider other risk management, if they buy at a point when the stock rockets 500% in a few weeks because Orange and China’s Winnie the Pooh are having another dick-measuring contest.
73 Likes
@Tokarczuk specifically reported their own movements and specs exemplarily and on time. I myself also managed to sell a bit above $11 after my comment here, when it started to feel too risky.
12 Likes
I even make it a practice to familiarize myself with companies mentioned by others on the forum, and I make my own investment decision before investing my money. Many quick trades have been left undone, and perhaps profits unrealized, but then I don’t have to blame the good discussions of others on the forum for my own decisions.
Regarding the topic of the thread itself, one can again wonder how quickly Mr. Market gets scared and then again forgets the reason for the scare. We will probably see the same thing many more times in the continuing episodes of the USA-China trade war.
37 Likes
Nordea at an all-time record. 14.72€
That’s all for me this time.
22 Likes
Veli Duell with a turnover of around 133,000 euros
5 Likes
I read some rumors about X, but nothing really explanatory that I’d dare to start spreading here! 
Someone knows something, or then just nothingburgers 
.
1 Like
Brother Nordea at ATH (All-Time High) figures. Still, analysts and market players: “More, buy”. It was difficult to find a weak spot in today’s earnings report, and once the economy starts to pick up, the numbers could fatten up nicely even more
I’m wondering if I should sell my Nordea slice at the ATH price and put it into a company like Huhtamäki, which is historically at a floor-level price. But half of Huhtamäki’s (Huhtis) revenue comes from the USA, and things are deteriorating there. Might get it even cheaper soon? In my calculations, Huhtamäki (Huhtis) is a €25-27 stock if the USA falters even a little.
10 Likes
Quamtum Scape next rocket? I’d guess some forum members also got burned in ABAT. Although based on the messages, they should be billionaires and not still hanging around here.
3 Likes
I placed a timid sell order on Nordea at €14.88. Valid for a limited time, only today. For many years, you could buy it at €10, and we wondered how cheap it was. Well, it paid off to stick with it. Still the largest in the portfolio, even though I’ve already lightened my position a bit at €12 - €14.
9 Likes
Well, well, the SANA pump apparently started yesterday.
It’s probably the same guy who just previously pumped OPEN.
“Sana Biotechnology Inc (NASDAQ:SANA) stock surged 20% Wednesday after EMJ Capital Eric Jackson declared the company could become “the next 100-bagger platform” in a series of posts on social media platform X.”
“Jackson, who previously spurred the dramatic rise in Opendoor Technologies this summer, highlighted Sana’s breakthrough in Type 1 Diabetes treatment, where a patient produced insulin following a single injection without requiring immunosuppression drugs.”
“The investor outlined a potential path to a $100 billion valuation, calculating that if Sana’s therapy reaches just 10% of the global Type 1 Diabetes population at $100,000 per patient, it could generate $90 billion in revenue. He suggested even 100,000 patients annually would yield $10 billion in sales.”
Now these numbers are starting to look like they’re pulled out of a hat again. However, it’s a Phase 1 company conducting n=2 trials with cadaveric beta-cell islets. Still a long way to 100 billion Of course, it could be that the hype train starts squeezing shorts and we go to the moon. Valuations don’t seem to matter that much anymore in this market 
2 Likes
I believe this was precisely the case, as he was the first to bring it up on the buy and sell board. I re-read the message and would have recommended the same to @belfastinbingviini as well. I will quote @Tokarczuk’s original text below. Although @belfastinbingviini tried to bring the phenomenon to light more generally, in the stock you criticized, the criticism was personified, more or less consciously, mainly towards him.
Based on the criticism, it remained unclear to me when it would be possible to write on the bought/sold page, if one shouldn’t be allowed to report their purchases even when generally describing the company’s operations, highlighting the clearest risks, the purchase price and quantity, the $10 target selling price, the target time for reaching the selling price, and later still reporting their sales roughly around the previously announced target selling price?
Now the problem became, if one can call it that in investing, that the stock rose to the $10 target price in about three weeks, and not within the originally stated one-year target period. Should @Tokarczuk be condemned because someone might have bought at his announced target price, or is the success of the investment being evaluated at the three-week mark when the target was originally set for a year out?
According to @belfastinbingviini, the justifications were thin? Let him who is without sin cast the first stone, as they say, so could you perhaps provide an example of one of your own messages where the matter was handled better?
Of course, I understand that depending on the reader, there may be aggravating factors involved, such as…
-
The stock must not be too hot or in momentum, because one can get burned. Currently, writers should therefore refrain from reporting purchases related to, for example, artificial intelligence, quantum computing, or rare earth metal mining in the USA.
-
The writer should stop writing on the buy/sell board when their successes and merits as an investor begin to be above average, because messages from such individuals are automatically interpreted as enticing.
Having followed the board, I’ve gotten the impression that at some point, almost every above-average reporter puts a damper on things because they can’t stand listening to the blaming for others’ choices, in this case, possibly made by others. This way, the average of those reporting their buys and sells is leveled closer to the average again, and nothing comes to mind that is more Finnish than this.
65 Likes
The spirit of the times is now that the numbers don’t really matter, as long as the stock price goes up. Quantum Scape is a cleverly chosen company name. Quantum is now in fashion. Foolishly, I’ve stuck with more traditional ones like Nordea and Fortum. Huge profits are being missed out on with these AI and quantum fads that I haven’t joined in on. I should probably still buy Palantir, even though that P/E =500 is quite salty 
1 Like
I myself have always been wary of all sorts of ‘bumtsibum hiphip hurraa’ shenanigans, even though one could make good money from them - if one hit the right company at the right time. However, a couple of weeks ago, I bought the VanEck Quantum Computing UCITS ETF, which was also hyped here, in a FOMO-induced state, and for an ETF, it has been quite, I would say, volatile. In a good direction, so far.
(Mega)trends also seem to be doing well; the defence sector has been a pleasant discovery for me, and I’ve been pumping money into it like a former groom. One just has to be a bit careful when the “mattress” runs out of air, so as not to be the last one at the party.
Let’s continue by saying that traditionally I have invested in such ‘rocket launchers’ as XACT Svenska Småbolag (YTD 1.14%) or XTrackers MSCI World Health Care (YTD -4.30%). Both defence and quantum computing are, by my standards, veritable rollercoasters.
6 Likes